Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Trevi Therapeutics Inc (NASDAQ: TRVI) closed at $4.22 up 3.69% from its previous closing price of $4.07. In other words, the price has increased by $3.69 from its previous closing price. On the day, 0.97 million shares were traded.
Ratios:
For a deeper understanding of Trevi Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.38 and its Current Ratio is at 7.38. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 12, 2024, Reiterated its Buy rating but revised its target price to $7.50 from $6 previously.
On August 30, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $9.Raymond James initiated its Outperform rating on August 30, 2024, with a $9 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 06 ’24 when GOOD JENNIFER L sold 4,219 shares for $3.03 per share. The transaction valued at 12,784 led to the insider holds 213,313 shares of the business.
GOOD JENNIFER L sold 1,840 shares of TRVI for $5,587 on Sep 09 ’24. The President & CEO now owns 213,313 shares after completing the transaction at $3.04 per share. On Sep 05 ’24, another insider, GOOD JENNIFER L, who serves as the President & CEO of the company, sold 40,277 shares for $3.11 each. As a result, the insider received 125,310 and left with 213,313 shares of the company.
Stock Price History:
Over the past 52 weeks, TRVI has reached a high of $4.68, while it has fallen to a 52-week low of $2.13. The 50-Day Moving Average of the stock is 8.70%, while the 200-Day Moving Average is calculated to be 33.75%.
Shares Statistics:
A total of 75.45M shares are outstanding, with a floating share count of 56.12M. Insiders hold about 37.21% of the company’s shares, while institutions hold 49.28% stake in the company.
Earnings Estimates
The stock of Trevi Therapeutics Inc (TRVI) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.11 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.45 and -$0.52 for the fiscal current year, implying an average EPS of -$0.48. EPS for the following year is -$0.49, with 7.0 analysts recommending between -$0.38 and -$0.63.
